239 related articles for article (PubMed ID: 1604320)
1. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected].
Milton RC; Milton SC; Kent SB
Science; 1992 Jun; 256(5062):1445-8. PubMed ID: 1604320
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease.
Tomaszek TA; Moore ML; Strickler JE; Sanchez RL; Dixon JS; Metcalf BW; Hassell A; Dreyer GB; Brooks I; Debouck C
Biochemistry; 1992 Oct; 31(42):10153-68. PubMed ID: 1420138
[TBL] [Abstract][Full Text] [Related]
3. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors.
Johnson EC; Malito E; Shen Y; Pentelute B; Rich D; Florián J; Tang WJ; Kent SB
J Mol Biol; 2007 Oct; 373(3):573-86. PubMed ID: 17869270
[TBL] [Abstract][Full Text] [Related]
4. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor.
Jaskólski M; Tomasselli AG; Sawyer TK; Staples DG; Heinrikson RL; Schneider J; Kent SB; Wlodawer A
Biochemistry; 1991 Feb; 30(6):1600-9. PubMed ID: 1993177
[TBL] [Abstract][Full Text] [Related]
5. Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule.
Torbeev VY; Kent SB
Angew Chem Int Ed Engl; 2007; 46(10):1667-70. PubMed ID: 17397076
[No Abstract] [Full Text] [Related]
6. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
[TBL] [Abstract][Full Text] [Related]
7. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
9. Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis.
Baca M; Kent SB
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11638-42. PubMed ID: 8265601
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of HIV-1 protease by interface peptides.
Schramm HJ; Billich A; Jaeger E; Rücknagel KP; Arnold G; Schramm W
Biochem Biophys Res Commun; 1993 Jul; 194(2):595-600. PubMed ID: 8343146
[TBL] [Abstract][Full Text] [Related]
11. Use of molecular dynamics and free energy perturbation calculations in anti-human immunodeficiency virus drug design.
McCarrick MA; Kollman P
Methods Enzymol; 1994; 241():370-84. PubMed ID: 7854189
[No Abstract] [Full Text] [Related]
12. Activities of precursor and tethered dimer forms of HIV proteinase.
Phylip LH; Griffiths JT; Mills JS; Graves MC; Dunn BM; Kay J
Adv Exp Med Biol; 1995; 362():467-72. PubMed ID: 8540359
[No Abstract] [Full Text] [Related]
13. Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors.
Petroková H; Dusková J; Dohnálek J; Skálová T; Vondrácková-Buchtelová E; Soucek M; Konvalinka J; Brynda J; Fábry M; Sedlácek J; Hasek J
Eur J Biochem; 2004 Nov; 271(22):4451-61. PubMed ID: 15560786
[TBL] [Abstract][Full Text] [Related]
14. Biomolecular mirror-image recognition: reciprocal chiral-specific DNA binding of synthetic enantiomers of zinc finger domain from GAGA factor.
Negi S; Dhanasekaran M; Hirata T; Urata H; Sugiura Y
Chirality; 2006 May; 18(4):254-8. PubMed ID: 16521086
[TBL] [Abstract][Full Text] [Related]
15. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies.
Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE
Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742
[No Abstract] [Full Text] [Related]
16. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
18. A folding inhibitor of the HIV-1 protease.
Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
[TBL] [Abstract][Full Text] [Related]
19. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
Quéré L; Wenger T; Schramm HJ
Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
[TBL] [Abstract][Full Text] [Related]
20. Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid.
Raju B; Deshpande MS
Biochem Biophys Res Commun; 1991 Oct; 180(1):187-90. PubMed ID: 1930215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
